145 related articles for article (PubMed ID: 31600808)
21. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer.
Fuentes HE; Oramas DM; Paz LH; Casanegra AI; Mansfield AS; Tafur AJ
Thromb Res; 2017 Jun; 154():28-34. PubMed ID: 28402864
[TBL] [Abstract][Full Text] [Related]
22. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
Rasmussen MS; Jørgensen LN; Wille-Jørgensen P
Cochrane Database Syst Rev; 2009 Jan; (1):CD004318. PubMed ID: 19160234
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
[TBL] [Abstract][Full Text] [Related]
24. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
Lu X; Lin J
BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
[TBL] [Abstract][Full Text] [Related]
26. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
Kirkilesis GI; Kakkos SK; Tsolakis IA
Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery.
Cohen AT; Hirst C; Sherrill B; Holmes P; Fidan D
Br J Surg; 2005 Nov; 92(11):1335-44. PubMed ID: 16237737
[TBL] [Abstract][Full Text] [Related]
28. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Castellucci LA; Cameron C; Le Gal G; Rodger MA; Coyle D; Wells PS; Clifford T; Gandara E; Wells G; Carrier M
JAMA; 2014 Sep; 312(11):1122-35. PubMed ID: 25226478
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological and Mechanical Thromboprophylaxis in Critically Ill Patients: a Network Meta-Analysis of 12 Trials.
Park J; Lee JM; Lee JS; Cho YJ
J Korean Med Sci; 2016 Nov; 31(11):1828-1837. PubMed ID: 27709864
[TBL] [Abstract][Full Text] [Related]
30. Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis.
Beitland S; Sandven I; Kjærvik LK; Sandset PM; Sunde K; Eken T
Intensive Care Med; 2015 Jul; 41(7):1209-19. PubMed ID: 25971389
[TBL] [Abstract][Full Text] [Related]
31. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z
J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261
[TBL] [Abstract][Full Text] [Related]
32. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
33. Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
Suen K; Westh RN; Churilov L; Hardidge AJ
J Arthroplasty; 2017 Sep; 32(9):2911-2919.e6. PubMed ID: 28522244
[TBL] [Abstract][Full Text] [Related]
34. Feasibility and safety of delivering full-dose anticoagulation therapy in children treated according to Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium therapy protocols.
Bhatt MD; Parmar N; Fowler JA; Chan AKC; Athale UH
Pediatr Blood Cancer; 2019 Feb; 66(2):e27483. PubMed ID: 30362248
[TBL] [Abstract][Full Text] [Related]
35. Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study.
Tuckuviene R; Ranta S; Albertsen BK; Andersson NG; Bendtsen MD; Frisk T; Gunnes MW; Helgestad J; Heyman MM; Jonsson OG; Mäkipernaa A; Pruunsild K; Tedgård U; Trakymiene SS; Ruud E
J Thromb Haemost; 2016 Mar; 14(3):485-94. PubMed ID: 26707629
[TBL] [Abstract][Full Text] [Related]
36. Safety of anticoagulant treatment in cancer patients.
Wilts IT; Bleker SM; Van Es N; Büller HR; Di Nisio M; Kamphuisen PW
Expert Opin Drug Saf; 2015 Aug; 14(8):1227-36. PubMed ID: 26059964
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of bridging with low molecular weight heparins: a systematic review and partial meta-analysis.
Eijgenraam P; ten Cate H; Ten Cate-Hoek A
Curr Pharm Des; 2013; 19(22):4014-23. PubMed ID: 23228321
[TBL] [Abstract][Full Text] [Related]
38. Anticoagulation for patients with cancer and central venous catheters.
Akl EA; Vasireddi SR; Gunukula S; Yosuico VE; Barba M; Sperati F; Cook D; Schünemann H
Cochrane Database Syst Rev; 2011 Apr; (4):CD006468. PubMed ID: 21491394
[TBL] [Abstract][Full Text] [Related]
39. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
van Der Heijden JF ; Hutten BA; Büller HR; Prins MH
Cochrane Database Syst Rev; 2000; (4):CD002001. PubMed ID: 11034739
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
